Navigation Links
FDA Approves New Indications for Prolia® (Denosumab) for the Treatment of Bone Loss in Patients With Prostate or Breast Cancer Undergoing Hormone Ablation Therapy
Date:9/19/2011

THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer.  In patients with prostate cancer, Prolia also reduced the incidence of vertebral fractures.  Prolia is the first-and-only therapy approved by the FDA for cancer treatment-induced bone loss in patients undergoing hormone ablation therapy.

Aromatase inhibitors are often used in patients with breast cancer to prevent recurrence of disease, and androgen deprivation therapy is often used in patients with prostate cancer to prevent or control recurrent disease. These treatments reduce hormone levels, leading to bone loss and an increased risk of fracture.

"Bone loss and fractures are recognized adverse effects of hormone ablation therapies but we have not had an approved treatment option to prevent these problems for our patients," said Matthew Smith, M.D., Ph.D., director of the Genitourinary Malignancies Program at Massachusetts General Hospital Cancer Center, Boston. "Prolia now gives us the ability to reduce the risk of bone loss and fractures, allowing patients to continue their treatment and their fight against cancer."

The expanded indications for Prolia are based on two Phase 3 clinical trials: a three year, randomized, double-blind, placebo-controlled, multinational study involving 1,468 men with non-metastatic prostate cancer undergoing androgen deprivation therapy, and a two year, double-blind, placebo-controlled, multinational study involving 252 postmenopausal women wi
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 With advancements in neurological ... market is seeing new growth, according to Kalorama ... account for the majority of market volume, newer ... images, which are creating opportunities for more sophisticated applications. ... growing at a rate of 4%, with world ...
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... LONDON , December 15, 2014 /PRNewswire/ ... Am 19. und 20. Februar ... das Aegate SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ... zu besuchen. Diese Tagung ... Gemeinschaft die Möglichkeit geben, die neue profitablen ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... by all subjects and sustained levels of drug ... Potentia Pharmaceuticals, a privately held biotechnology company developing ... (AMD), announced today that it successfully completed its ... POT-4 Therapy for Patients with Neovascular Age-Related Macular ...
... $55 Million in Near Term Payments -CAMBRIDGE, Mass., ... that the company has entered into an out-licensing ... to develop and commercialize the investigational compound linaclotide ... constipation (IBS-C) and other gastrointestinal conditions. This agreement ...
Cached Medicine Technology:Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II 2Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II 3Ironwood Announces Linaclotide European Licensing Agreement with Almirall 2Ironwood Announces Linaclotide European Licensing Agreement with Almirall 3
(Date:12/21/2014)... Concept Plus, LLC. a SDB and ... Fairfax, VA., today announced it has been recognized by ... which ranks the fastest growing government contracting small businesses by ... , This is the first year that Concept Plus, LLC., ... with a 95.92% compound annual growth rate. “For Concept Plus ...
(Date:12/20/2014)... a distinguished special dress supplier, has just done something ... cut prices to all its prom dresses already, offering ... Many of the hottest styles are sold here like ... more. , A spokesman for MissyDress says, “The great ... prom dresses or sweetheart chiffon prom dresses, you will ...
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... SATURDAY, Dec. 20, 2014 (HealthDay News) -- The holidays ... when they contend with fresh trees, scented candles and ... and on the decorations that have been packed away ... in my allergy and asthma patients," Dr. Rachna Shah, ... School of Medicine, said in Loyola news release. ...
(Date:12/20/2014)... Angeldress.co.uk, the distinguished wedding dress manufacturer and retailer, ... The company has recently updated its official blog with ... season, Angeldress Blog has recommended some new ... prides itself in offering a huge selection of elegant ... company’s outfits are very carefully selected based on the ...
Breaking Medicine News(10 mins):Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2
... A review and analysis of previously published studies finds ... relationships between medicine and industry should be disclosed, in ... clinical care, according to a report in the April ... one of the JAMA/Archives journals. "Financial ties to ...
... development of screening tests for early detection , MONDAY, April ... of ovarian cancer may lead to the development of a ... In the study, scientists uncovered early tumors and precancerous lesions ... surface. , "This is the first study giving very strong ...
... fruits and veggies die earlier than usual, study finds , ... unhealthy behaviors -- smoking, lack of exercise, poor diet and ... death, a new study has found. , The study, published ... Medicine , included 4,886 people, aged 18 or older, who ...
... (ASTRO) applauds President Obama,s selection of Donald Berwick, M.D., ... Medicare and Medicaid Services. ASTRO looks forward to working ... implement critical healthcare reforms for patients and work toward ... the quality of care patients receive. ASTRO,s highest priority ...
... Lisa P. Jackson and NASA Administrator Charles Bolden ... education at the Howard University Middle School of ... chose the Howard University Middle School to underscore ... the next generation of leaders. The administrators also ...
... researchers say , MONDAY, April 26 (HealthDay News) -- It ... for colon cancer, a new study suggests. , Researchers analyzed ... cancer-free people. They identified unusual levels of 16 substances in ... tryptophan, one of the 22 amino acids found in proteins. ...
Cached Medicine News:Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Study Makes Strides in Understanding Ovarian Cancer 2Health News:Four Unhealthy Behaviors Linked to Premature Death 2Health News:EPA and NASA administrators to extend environmental and Earth science agreement 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: